Published: June 22, 2026 · Last reviewed: June 22, 2026

Which GLP-1 Is Easiest to Stay On?

Jump to: Why people quit · Stay-On Fit Matrix · Side effects · Cost & coverage · Needles & pills · Compounded · Providers · Bottom line · FAQ

Is this page for you?

Best for you if: you want to start a GLP-1 but you're scared you won't be able to keep taking it; you're choosing between Zepbound, Wegovy, the Wegovy pill, Foundayo, Saxenda, or a compounded program; you care more about staying on long enough to see results than about chasing the single biggest weight-loss number.

Not for you if: you only want a “best GLP-1 for weight loss” ranking — that's a different question, see our best GLP-1 for fastest weight loss guide; or you want compounded and FDA-approved medications treated as the same thing (they aren't, and we won't pretend they are).

Start here: match the medication to your biggest worry

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

What does “easiest to stay on” actually mean?

“Easiest to stay on” means the medication fits your real life well enough that you keep taking it. For GLP-1s, that comes down to four things: side effects, dosing routine, cost, and reliable access. Real-world studies show about half of people stop their GLP-1 within the first year — and the reasons are more about life and money than willpower.

In a nationwide Danish study of 77,310 adults taking semaglutide for weight loss, presented at EASD 2025, 52% had stopped within one year — 18% by three months, 31% by six, and 42% by nine. A large U.S. records analysis of 125,474 people found that within 12 months, 46.5% of people with type 2 diabetes and 64.8% of people without diabetes had stopped, though some later restarted (JAMA Network Open, 2025).

Now the part almost no other page tells you. When researchers looked at why 288 people actually quit their semaglutide or tirzepatide in the first year (Gasoyan et al., Obesity, 2025):

Source: Gasoyan et al., Obesity, 2025.

The RX Index Stay-On Fit Matrix

This table does something no single competitor page does: it scores each treatment path on all four things that actually make people quit, with real label numbers and current prices side by side. Last verified: June 22, 2026. Prices change — recheck before you rely on them.

If side effects are what scares you — which GLP-1 is gentlest?

There's no guaranteed “gentlest” GLP-1 for every person, but the label data gives useful signals. Across the medications, fewer people stop for side effects when the dose is raised slowly. In the one head-to-head trial, fewer people stopped tirzepatide than semaglutide because of side effects.

Side-effect signal by medication (from each drug's own FDA label)

The real trick to staying on: go slow

Almost every label says the same thing — most people who quit for side effects do it in the first few months, during the dose climb, and most nausea and diarrhea fade over time. The single biggest thing you can control is titration — the slow, step-by-step raising of your dose. A provider who rushes you to a high dose is also raising your odds of quitting.

Simple habits that help many people ride out the early weeks: eat smaller meals, stop when you're full, drink water, go easy on greasy and rich food, and tell your provider before you quit — there's almost always an adjustment to try first. (This is general guidance, not a treatment plan. Your clinician sets your dose.)

If cost or insurance is the worry — which GLP-1 is most sustainable?

Cost is the single most common reason people stop a GLP-1 — about 48% of those who quit (Gasoyan et al., Obesity, 2025). So for most people, the “easiest to stay on” answer is whichever FDA-approved medication their insurance covers, or one with a real savings program — not whichever has the fewest side effects. A drug you tolerate but can't afford isn't easier. It's a future quit waiting to happen.

Remember the timing: people who quit over money tend to quit later, once a coupon expires or a plan denies coverage. The smart move is to nail down your real monthly cost and your coverage before you start, not after.

2026 self-pay cost snapshot (verified June 22, 2026 — recheck before you rely on it)

Why insurance navigation matters — and where Ro fits

The real lever for staying on isn't just the sticker price — it's navigating insurance. Getting a prior authorization approved, checking your coverage, and appealing a denial are the steps that keep people on treatment. This is where the provider changes the outcome, not just the medication.

If needles are the dealbreaker — is a pill easier to stay on?

A daily pill removes the needle barrier, but it trades it for two others: a stricter routine and far less long-term data. Foundayo (orforglipron) is the only GLP-1 pill you can take any time, with or without food. The Wegovy pill works too, but its empty-stomach, tiny-sip-of-water, then-wait rule trips a lot of people up.

Wegovy vs Zepbound: which is easier to stay on?

In the one head-to-head trial, fewer people stopped Zepbound (tirzepatide) than Wegovy (semaglutide) for stomach side effects — 2.7% vs 5.6% — and Zepbound produced more weight loss (SURMOUNT-5, New England Journal of Medicine, 2025). But both are once-weekly, both are FDA-approved, and for staying on, the deciding factor is usually your coverage and cost, not a small tolerability gap.

• Choose Zepbound if you want once-weekly tirzepatide, you're comfortable with a shot, and you can keep access through insurance or LillyDirect ($299–$449/mo by dose).
• Choose Wegovy if you prefer semaglutide, you might want the pill option later, or your plan covers Wegovy with less hassle.

Why compounded GLP-1s are now the hardest to stay on

Compounded semaglutide and tirzepatide were a cheap on-ramp during the 2022–2024 shortages. Those shortages are over, and the path that allowed large-scale compounding has closed. They are not FDA-approved, and in April 2026 the FDA proposed permanently restricting large-scale compounding of them — which makes them the least reliable option to build a long-term plan around.

Quick definition: a compounded drug is mixed by a pharmacy for a specific patient, instead of being a finished medicine the FDA reviewed and approved. During the shortages, pharmacies were allowed to make copies of semaglutide and tirzepatide. The FDA declared the shortages resolved — tirzepatide in December 2024, semaglutide in February 2025 — and the windows for mass-compounding them closed in spring 2025. On April 30, 2026, the FDA proposed permanently keeping semaglutide, tirzepatide, and liraglutide off the list that lets large “outsourcing facilities” compound them in bulk (Federal Register; comment period closed June 29, 2026). It's a proposal, not a final rule yet — but the direction is clear.

On safety: the FDA has logged 990 reports of problems linked to compounded semaglutide and more than 730 linked to compounded tirzepatide (as of May 31, 2026) — and it notes these are likely undercounted. The FDA can't always tell whether the drug caused each event, but the pattern, plus reports of dosing errors and fake products, is enough that the agency keeps warning against them.

If you're on a compounded GLP-1 right now, this doesn't mean stop today — it means plan your move to an FDA-approved option with a provider, so a sudden supply cutoff doesn't catch you mid-treatment.

What happens if you stop a GLP-1?

If you stop, some weight regain is common — because obesity is a long-term condition the medication manages, not cures. But real-world regain is often modest, and many people restart or switch rather than lose all their progress. Knowing this takes the “trapped forever” fear out of the decision.

The largest real-world look at this, a Cleveland Clinic study of nearly 8,000 patients, found that people treated for obesity lost about 8.4% of their body weight, then regained only about 0.5% on average a year after stopping; roughly half kept losing or held steady, and many restarted (Diabetes, Obesity and Metabolism, 2026). That's gentler than the trial picture — in the STEP 1 trial, people regained about two-thirds of their lost weight within a year of stopping (JAMA, 2022). The difference is real life: switching meds, lifestyle changes, and staying connected to care.

The takeaway loops back to the whole point of this page: the best plan is the one you can keep, safely and affordably, with a clinician in the loop. That's why matching the medication to your real barrier beats chasing the strongest number.

How to give yourself the best odds of staying on

You improve your odds by solving your quit risk before it happens: lock in your real monthly cost, pick a routine you'll actually follow, ask about a slow dose plan, and have a side-effect game plan ready before your first dose. People who plan for the hurdle clear it far more often than people who get surprised by it.

Fill this in before you start your first dose. It takes five minutes and it's the single best predictor of whether you'll still be on track in six months:

A good clinician will help you with the dose climb and the side-effect plan; a good provider will help you with cost, coverage, and refills. Get both lined up and you've removed the top reasons people quit — before they happen.

Who should not choose based on “easiest” alone

Some people need a clinician's judgment before convenience even enters the picture. A few specifics straight from the labels:

• Severe gastroparesis (very slow stomach emptying): Foundayo, Zepbound, Wegovy, and Saxenda are not recommended if you have severe gastroparesis.
• Thyroid cancer risk: Foundayo, Zepbound, Wegovy, and Saxenda all carry a boxed warning for thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2.
• Birth control pills + tirzepatide or Foundayo: Both can slow stomach emptying and may affect how oral birth control is absorbed. Zepbound's label advises a backup method for 4 weeks after starting and each dose increase; Foundayo's says to use a non-oral or backup method for 30 days after starting and after each dose increase. Ask your provider.
• Insulin or sulfonylureas: The risk of low blood sugar can rise when a GLP-1 is combined with insulin or certain diabetes pills; your doses may need adjusting.
• Pregnancy or planning pregnancy: GLP-1 labels carry pregnancy and fetal-risk warnings, and advise stopping when a pregnancy is recognized. If you're pregnant, planning to be, or could become pregnant, this is clinician-first — not a convenience choice.

None of this is a reason to avoid GLP-1s — it's a reason to start with a real clinical conversation. The quiz routes people with these flags toward a provider who'll review their history, not just a checkout page.

Which provider makes a GLP-1 easiest to stay on?

The provider can matter as much as the medication, because refills, insurance help, steady pricing, and dose support all decide whether you keep going. For FDA-approved options on this question, Ro and Sesame Care are the two paths we'd point most people to first. The reason ties back to the data: cost and access are the top reasons people quit, so the provider that helps most with coverage and reliable refills is the one that helps you stay on.

Already quit a GLP-1 once? Start with why

If you already stopped a GLP-1, your next decision should start with the reason you quit. Side effects, cost, insurance denials, and shortages each point to a different fix — and matching the fix to the reason is how a second attempt sticks.

Bottom line: which GLP-1 should you ask about first?

Ask about the treatment path that removes your biggest quit risk. Weekly simplicity → Zepbound or Wegovy. Needle fear → Foundayo or the Wegovy pill. Cost worry → an FDA-approved option with coverage help, verified before you start.

How we built this guide — and what we actually verified

This page is maintained by The RX Index Editorial Team. We compared the actual FDA labels, manufacturer pricing and dosing pages, and peer-reviewed discontinuation research. We don't accept payment to change our scoring.

What we verified for this update (June 22, 2026):

• FDA label data on side effects and discontinuation for Zepbound, Wegovy (shot and pill), Saxenda, and Foundayo.
• The head-to-head tolerability and weight-loss numbers from SURMOUNT-5 (New England Journal of Medicine, 2025).
• Real-world quit rates and reasons (Danish study at EASD 2025; JAMA Network Open 2025; Gasoyan, Obesity 2025).
• Foundayo's FDA approval and stated pricing (FDA and Eli Lilly, April 2026).
• Current self-pay pricing for Zepbound (LillyDirect) and Wegovy (NovoCare), checked June 2026.
• The FDA's current position on compounded GLP-1s, including the April 30, 2026 proposal and 990 / 730+ adverse-event report counts (FDA, updated June 15, 2026).
• What happens after stopping (Cleveland Clinic, Diabetes, Obesity and Metabolism 2026).

Prices and policies change. We re-check commercial data monthly and medical data quarterly.

FAQ: Which GLP-1 is easiest to stay on?

Sources

• Zepbound (tirzepatide) prescribing information — FDA / DailyMed. Accessed June 22, 2026.
• Zepbound self-pay pricing — LillyDirect / Eli Lilly. Accessed June 22, 2026.
• Wegovy (semaglutide) injection and tablet prescribing information — FDA / DailyMed. Accessed June 22, 2026.
• Wegovy price guide — NovoCare. Accessed June 22, 2026.
• Saxenda (liraglutide) prescribing information — FDA / DailyMed. Accessed June 22, 2026.
• Foundayo (orforglipron) prescribing information — FDA / DailyMed; FDA approval and pricing, Eli Lilly news release, April 1, 2026.
• Tirzepatide vs semaglutide (SURMOUNT-5) — Aronne LJ et al., New England Journal of Medicine, 2025;393:26–36.
• Real-world discontinuation (semaglutide, Denmark) — Thomsen et al., presented at EASD 2025.
• Discontinuation and reinitiation (125,474 adults) — JAMA Network Open, 2025.
• Reasons for discontinuation — Gasoyan et al., Obesity, 2025.
• Weight change after stopping — Cleveland Clinic newsroom, March 12, 2026 / Diabetes, Obesity and Metabolism, 2026; STEP 1, JAMA, 2022.
• FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, updated June 15, 2026.
• Compounded GLP-1 status — FDA shortage resolution (December 2024 / February 2025); 503B bulks-list proposal, Federal Register, April 30, 2026.
• Hims & Hers / Novo Nordisk agreement — company announcements, March 9, 2026.

The RX Index is an independent editorial publisher. We score GLP-1 providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost. We are not affiliated with Eli Lilly, Novo Nordisk, or any drug manufacturer. We may earn a commission if you visit a provider through our links.